Our data also support the use of specific NLRP3 inhibitors, such as MCC950, to attenuate inflammasome-related responses during COVID-19, since this drug was able to abrogate ex-vivo IL-1β secretion, conversely to colchicine, which decreased TNF-α release. This evidence concerns the gene NLRP3 and COVID-19.